MedPath

A Stepped-wedge Cluster Randomized Controlled Trial for Evaluating an Intervention in Patients With Stroke Tailored Education in Addition to Physiotherapist Treatment

Not Applicable
Withdrawn
Conditions
Stroke
Interventions
Other: Multimodal intervention
Registration Number
NCT02681146
Lead Sponsor
University of Malaga
Brief Summary

A stepped-wedge cluster design will be used, with the duration of the trial being 50 weeks. The 'stepped-wedge ' cluster randomised trial is a form of cross-over design with unidirectional cross-over ( from control to experimental ) but with randomisation of when each cluster undertakes this transition. In the stepped-wedge design, there is a staggered roll-out of the intervention, where the time and hence the sequence of units (clusters) that will start the intervention at each period is determined by random allocation.

The randomisation occurs before the start of the trial. All clusters start the trial in a control phase with no intervention being delivered at any site, then sequentially cross over from the control group to the intervention group, until all sites are receiving the intervention. Outcomes are measured on the study participants in all clusters at every time period, hence measurement of outcomes takes place at each step in the wedge; each cluster provides data points in the control and intervention conditions allowing each site to act as its own control.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • The study subjects were all patients who had been hospitalised in 8 regional hospitals of Andalusian Health Service with acute cerebral stroke, clinically stable, presented an ischaemic or haemorrhagic aetiology and clinical symptoms of hemiplegia, were selectioned to receiving physiotherapy in hospitalisation, were assisted by a caregiver, had an adequate understanding of Spanish, and had given their written informed consent.
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group6Multimodal interventionEducational advice + physiotherapist treatment
Group1Multimodal interventionEducational advice + physiotherapist treatment
Group3Multimodal interventionEducational advice + physiotherapist treatment
Group4Multimodal interventionEducational advice + physiotherapist treatment
Group7Multimodal interventionEducational advice + physiotherapist treatment
Group8Multimodal interventionEducational advice + physiotherapist treatment
Group2Multimodal interventionEducational advice + physiotherapist treatment
Group5Multimodal interventionEducational advice + physiotherapist treatment
Primary Outcome Measures
NameTimeMethod
Canadian Neurological Scale (CNS):8 weeks

Measures neurological status of stroke (psychometric properties: Spearman correlation coefficient of 0.924 (95% CI: 0.896-0.951) and internal consistency by Cronbach's alpha of 0.792, N=155

Secondary Outcome Measures
NameTimeMethod
Trunk Control Test (TCT):8 weeks

scores trunk control (psychometric properties: inter-rater reliability by Spearman's correlation coefficient r=0.76; internal consistency by Cronbach's alpha 0.83-0.86).

Barthel Index (BI)8 weeks

scores the patient's ability to perform activities of daily living (ADL) (inter-observer reliability by Kappa indices 0.47-1.00; intra-observer reliability by Kappa indices 0.84-0.972; internal consistency by Cronbach's alpha 0.86-0.92).

Stroke Impact Scale-16 (SIS-16):8 weeks

measures the deficits and physical limitations provoked by stroke (ADL, mobility and hand function) (internal consistency by Cronbach's alpha 0.87-0.95).

Modified Rankin Scale (MRS)8 weeks

to score the incapacity of the patient (inter-observer reliability by Kappa indices (k=0.56 to k=0.78). Good test-re-test reliability (k=0.81 to k=0.95).

Motricity index (MI) of the lower and upper limbs8 weeks

measures upper and lower limb strength (Spearman's correlation coefficient of 0.87 (p\<0.001) for MI-LL, and of 0.88 (p\<0.001) for MI-UL).

Multidimensional Scale of Perceived Social Support (MSPSS)8 weeks
© Copyright 2025. All Rights Reserved by MedPath